GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » Equity-to-Asset

Asarina Pharma AB (OSTO:ASAP) Equity-to-Asset : 0.27 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Asarina Pharma AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Asarina Pharma AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr1.65 Mil. Asarina Pharma AB's Total Assets for the quarter that ended in Dec. 2023 was kr6.08 Mil.

The historical rank and industry rank for Asarina Pharma AB's Equity-to-Asset or its related term are showing as below:

OSTO:ASAP's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Asarina Pharma AB Equity-to-Asset Historical Data

The historical data trend for Asarina Pharma AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Equity-to-Asset Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.85 0.77 0.70 0.87 0.27

Asarina Pharma AB Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.91 0.87 0.69 0.27

Competitive Comparison of Asarina Pharma AB's Equity-to-Asset

For the Biotechnology subindustry, Asarina Pharma AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asarina Pharma AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's Equity-to-Asset falls into.


;
;

Asarina Pharma AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Asarina Pharma AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1.649/6.077
=

Asarina Pharma AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1.649/6.077
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asarina Pharma AB  (OSTO:ASAP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Asarina Pharma AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Asarina Pharma AB Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB Headlines

No Headlines